Thesis--Auburn University, 2009. / Abstract. Includes bibliographic references (p.68-75).

Thesis (Ph. D.)--University of Chicago, Dept. of Political Science, December 1999. / Includes bibliographical references. Also available on the Internet.

Thesis (M.A.)--University of Missouri-Columbia, 2007. / The entire dissertation/thesis text is included in the research.pdf file; the official abstract appears in the short.pdf file (which also appears in the research.pdf); a non-technical general description, or public abstract, appears in the public.pdf file. Title from title screen of research.pdf file (viewed on November 12, 2007) Includes bibliographical references.

Class of 2015 Abstract / Objectives: The objective of the study is to describe which factors influence career choice in Pharm.D. candidates, and determine what makes a potential employer attractive to graduating students. Methods: A descriptive focus group study was conducted to describe opinions of Pharm.D. candidates regarding factors that determine career choice. Subjects were recruited via email. All participants were required to have a scheduled graduation date in 2015 or 2016. Demographic data was collected anonymously. Focus group conversations were recorded. Results: There were 13 participants, 8 female (61.5%) and 5 male (38.5%). Six (46.2%) hope to work in the retail setting after graduation, and 5 (38.5%) wish to work in an institutional setting. Four participants (30.1%) plan to complete a PGY1 residency after graduation. Ten participants (76.8%) agree that they would consider working for their current employer after graduation from pharmacy school. The majority of participants changed their mind throughout their education in regards to their future career choice. Rotations, professors, employers, and family seem to be the most common factors that helped determine career choice in participants. All participants agreed that clinical pharmacy and residency are promoted career paths at University of Arizona. Conclusions: The clinical pharmacy career path is believed to be strongly promoted at the University of Arizona. Rotations, professors, family, and employers during pharmacy school appear to be determining factors in career choice for Pharm.D. candidates. Many students pursue a career with the same employer they had during their education.

Thesis (M.A.) -- University of Texas at Arlington, 2008.

Thesis (doctoral)--Uppsala University, 2004. / Includes bibliographical references (p. [275]-313).

Thesis (doctoral)--Uppsala University, 2004. / Includes bibliographical references (p. [275]-313).

No description available.

No description available.

Class of 2006 Abstract / Objectives: To investigate the types of information and resources either used or required for the management of products in the pipeline as perceived by decision-makers in the biotechnology and pharmaceutical (B&P) industries. More specifically, the objectives are to ascertain the strategic use of pharmacoeconomic (PE), financial, and decision- making tools and financing requirements amongst pipeline candidates. Methods: A study-specific survey instrument was used for the project. In detail, this survey is based upon the use of financial, PE, and decision-making tools for drug product development. Approximately 396 B&P firms were surveyed via postal mail, wherein the primary contact was the Chief Financial Officer (CFO). If the CFO was not listed on the firm’s website, the survey will be addressed to the Business and Development Officer (BDO) or Chief Executive Officer (CEO). The companies’ information will be identified by use of publicly-available databases. A modified form of a total survey design will be used for the postal mailings, including one initial mailing with a cover letter and survey, a follow-up reminder postcard, a second cover letter and survey for non-responders, and a final follow-up reminder postcard then after. Results: Survey instruments were completed by 20 firms, with 5 of them from public firms and 15 from the private sector. Capital and regulatory requirements and investor expectations are the most important factors considered during early and late phase clinical trials. Net present value (NPV) and internal rate of return (IRR) are the most commonly used financial analytic tools used for making research and development (R&D) decisions. PE are reported to be first used during all clinical phases prior to Food and Drug Administration (FDA) approval, and most drug candidates undergo formal PE evaluations. PE is also used in various areas of R&D and marketing components, such as licensing and go/no-go decisions. Capital/securities markets and venture capital (VC) are the primary sources of capital used in the development of a new drug. VC is important during all phases of R&D and numerous VC firms get involved. B&P firms disagree that VC companies should be involved with the managerial roles of the firm. Conclusions: It has been determined that the strategic use of PE, financial and decision-making tools, and capital requirements amongst pipeline candidates are important during all phases of R&D.